Non-Hodgkin's Lymphoma Pipeline Analysis Report 2026

Non-Hodgkin’s lymphoma (NHL) is a diverse group of blood cancers that originate in the lymphatic system and are distinguished from Hodgkin’s lymphoma by the absence of Reed-Sternberg cells. Globally, NHL represents nearly 45% of all lymphoma cases, with a higher incidence among older adults. According to the non-Hodgkin’s lymphoma pipeline analysis, the pipeline encompasses monoclonal antibodies, small molecules, gene therapies, and cell-based therapies targeting both aggressive and indolent subtypes. The rising adoption of targeted lymphoma therapy, precision oncology treatments, and immuno-oncology drugs, along with increasing disease burden and unmet clinical needs, is expected to support growth in the non-Hodgkin’s lymphoma treatment and the broader oncology therapeutics pipeline.

Report Coverage

The Non-Hodgkin’s Lymphoma Pipeline Analysis Report gives comprehensive insights into non-Hodgkin’s lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The non-Hodgkin’s lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with non-Hodgkin’s lymphoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to non-Hodgkin’s lymphoma.

Non-Hodgkin’s Lymphoma Pipeline Outlook

Non-Hodgkin’s lymphoma is a malignancy affecting the lymphatic system, primarily involving B-cells or T-cells. It occurs due to uncontrolled proliferation of abnormal lymphocytes, leading to tumor formation in lymph nodes, spleen, or other organs, often accompanied by fatigue, fever, swollen lymph nodes, and recurrent infections.

Non-Hodgkin’s lymphoma treatment approaches include chemotherapy, targeted therapy, immunotherapy, radiation, and stem cell transplantation aimed at controlling disease progression and eliminating malignant cells. The growing adoption of novel lymphoma treatment options and advanced biologic therapies is reshaping the treatment paradigm. In June 2025, zanubrutinib (Brukinsa®) was approved in the UK as a treatment for relapsed or refractory mantle cell lymphoma. This oral Bruton tyrosine kinase inhibitor provides patients with an effective, convenient, home-based therapy option, reducing hospital visits.

Non-Hodgkin’s Lymphoma Epidemiology

Non-Hodgkin lymphoma (NHL) represents nearly 45% of all lymphoma cases, with the majority (85-90%) arising from B cells and the remainder from T cells or natural killer cells, as reported by Xiaobo Luo et al., 2025. In 2021, NHL contributed to approximately 962,474 disability-adjusted life years (DALYs) globally, with an age-standardized death rate (ASDR) of 13.535 per 100,000. South Asia experienced the highest regional DALYs, while Australasia reported the lowest. Eastern Sub-Saharan Africa had the highest ASDR, and High-Income North America the lowest. From 1990-2021, Southern Sub-Saharan Africa showed the largest ASDR increase, contrasted by a significant decrease in East Asia.

Non-Hodgkin’s Lymphoma - Pipeline Therapeutic Assessment

This section of the report covers the analysis of non-Hodgkin’s lymphoma drug candidates based on several segmentations, including:

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase 1)
• Preclinical and Discovery Stage Products

By Drug Class

The non-Hodgkin’s lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptides
• Cell Therapies

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

By Phase

The pipeline assessment report covers 50+ drug analyses based on phase:

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase 1)
• Preclinical and Discovery Stage Products

By Drug Class

The non-Hodgkin’s lymphoma pipeline analysis report covers 50+ drug analyses based on drug classes:

• Small Molecules
• Monoclonal Antibodies
• Peptides
• Cell Therapies

By Route of Administration

The pipeline assessment report covers 50+ drug analyses based on the route of administration:

• Oral
• Parenteral
• Others

Non-Hodgkin’s Lymphoma Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total non-Hodgkin’s lymphoma clinical trials, accounting for 50% of developments. It is followed by phase II at 40%. This trend highlights strong innovation in early development stages and growing investment in experimental cancer therapies and clinical-stage oncology drugs, which are expected to significantly influence the growth.

Non-Hodgkin’s Lymphoma Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the non-Hodgkin’s lymphoma pipeline analysis include small molecules, monoclonal antibodies, peptides, and cell therapies. The non-Hodgkin’s lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for non-Hodgkin’s lymphoma. Targeted combination therapies are gaining attention in the non-Hodgkin’s lymphoma pipeline to improve treatment outcomes. For example, the ViPOR regimen, a five-drug combination including venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, is under Phase Ib/II evaluation for relapsed or refractory diffuse large B-cell lymphoma.

This strategy targets multiple molecular pathways, improving tumor reduction and patient response rates while advancing precision medicine in oncology.

Non-Hodgkin’s Lymphoma Clinical Trials - Key Players

The report for the non-Hodgkin’s lymphoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed non-Hodgkin’s lymphoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in non-Hodgkin’s lymphoma clinical trials:

• Sichuan Baili Pharmaceutical Co., Ltd.
• Beijing Mabworks Biotech Co., Ltd.
• ImmunityBio, Inc.
• Shanghai Junshi Bioscience Co., Ltd.
• Estrella Biopharma, Inc.
• AbbVie
• Sana Biotechnology
• Hoffmann-La Roche
• Regeneron Pharmaceuticals
• Hrain Biotechnology Co., Ltd.
• Nanjing IASO Biotechnology Co., Ltd.
• Ascentage Pharma Group Inc.

Non-Hodgkin’s Lymphoma - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for non-Hodgkin’s lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of non-Hodgkin’s lymphoma drug candidates.

Drug: GNC-038

GNC-038 is an octavalent, tetra-specific antibody being developed by Sichuan Baili Pharmaceutical Co., Ltd. for patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL). The drug functions as a CD19-specific T cell engager, simultaneously targeting PD-L1 and 4-1BB to activate T cells and directly attack malignant cells. Administered via intravenous infusion once weekly, GNC-038 is currently in a Phase Ib/II study exploring its safety, tolerability, pharmacokinetics, and antitumor activity. The Phase Ib portion is determining the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D), while Phase II is assessing preliminary efficacy in NHL patients. Preclinical studies indicate strong anti-tumor activity and favorable pharmacokinetics.

Drug: MBS303

MBS303 is an innovative CD20/CD3 T-cell engager being developed by Beijing Mabworks Biotech Co., Ltd. This Phase I/II study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of MBS303 administered via intravenous infusion in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. MBS303 functions by redirecting T-cells to selectively target and eliminate CD20-positive B-cells, enhancing immune-mediated tumor destruction. The study is structured with a dose-escalation Phase I followed by a Phase II expansion, aiming to identify optimal dosing and preliminary therapeutic benefit. Results are expected to guide future clinical development.

Drug: N803

CD19 t-haNK, sponsored by ImmunityBio, Inc., is undergoing a Phase 1, first-in-human study to evaluate its safety as a single agent and in combination with rituximab, with or without the IL-15 superagonist N-803, in subjects with relapsed or refractory Non-Hodgkin’s Lymphoma (R/R NHL). This open-label study examines the drug’s safety, tolerability, and preliminary efficacy through intravenous administration following lymphodepleting chemotherapy. CD19 t-haNK is an engineered natural killer cell therapy targeting CD19-positive B cells, while N-803 stimulates proliferation of NK and T cells, enhancing the immune response. Up to 20 subjects are being enrolled to assess safety and preliminary efficacy.

Key Questions Answered in the Non-Hodgkin’s Lymphoma Pipeline Insight Report

• Which companies/institutions are leading non-Hodgkin’s lymphoma drug development?
• Which company is leading the non-Hodgkin’s lymphoma pipeline development activities?
• What is the current non-Hodgkin’s lymphoma commercial assessment?
• What are the opportunities and challenges present in the non-Hodgkin’s lymphoma pipeline landscape?
• What is the efficacy and safety profile of non-Hodgkin’s lymphoma pipeline drugs?
• Which company is conducting major trials for non-Hodgkin’s lymphoma drugs?
• Which companies/institutions are involved in non-Hodgkin’s lymphoma collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in non-Hodgkin’s lymphoma?

Reasons To Buy This Report

The Non-Hodgkin’s Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for non-Hodgkin’s lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into non-Hodgkin’s lymphoma collaborations, regulatory environments, and potential growth opportunities.